Lovastatin is a first-generation statin, a class of drugs that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. By lowering LDL cholesterol and Apolipoprotein B (ApoB), it directly reduces the accumulation of atherosclerotic plaque in arteries. For healthspan, this translates to a significant reduction in the lifelong risk of cardiovascular events like heart attacks and strokes, which are primary drivers of age-related mortality and morbidity.
Verdict
A foundational tool for managing cardiovascular risk, a pillar of healthspan.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$4 - $20
Protocol
- Doses are titrated to achieve target ApoB or LDL-C levels, typically 20-80 mg daily.
Flags
- Common side effects include myopathy (muscle pain) and potential liver enzyme elevation.
- Associated with a small but statistically significant increased risk of new-onset type 2 diabetes.
- Interacts with grapefruit juice and certain antifungal and antibiotic medications (CYP3A4 inhibitors).
- Rare but serious risk of rhabdomyolysis, especially when combined with other drugs.